Flavio G Rocha, Hedinger Chair of Surgical Oncology and Physician-in-Chief at OHSU Knight Cancer Institute, shared a post by Gagan Brar, Assistant Clinical Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope, on X, adding:
“Interesting results from a single, high-volume center in China with adjuvant immunotherapy plus capecitabine following resection of intrahepatic cholangiocarcinoma.
Perioperative strategies may be the way forward.”
Quotting Gagan Brar‘s post:
“Adjuvant anti-PD-1 plus capecitabine in resected iCCA shows median recurrence-free survival similar to the per-protocol analysis of adjuvant capecitabine monotherapy, while median overall survival is not reached.
Not better – perhaps related to micrometastases at diagnosis. Should we be prioritizing neoadjuvant treatment strategies instead?”
Title: Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
Authors: Prof Zheng Wang, Lixing Li, Peiran Huang, Honghu Tu, Xiangyu Zhang, Lei Yu, Fei Liang, Prof Cheng Huang, Prof Shuangjian Qiu, Prof Qinghai Ye, Prof Zhenbin Ding, Prof Xiaowu Huang, Prof Yinghong Shi, Kang Song, Prof Huichuan Sun, Prof Xiaoying Wang, Yongfeng Xu, Yao Yu, Prof Qiang Gao, Prof Lan Zhang, Prof Jia Fan, Prof Jian Zhou
More posts featuring Flavio G Rocha.